The inhibitory effect of GSK-J4 is likely achieved by inhibiting the ability of KDM6B to epigenetically alter the activation of the NF-κB pathway, which is required together with KDM6B for the adhesion of MCL cells to stromal cells. Here, KDM6B is linked to mantle cell lymphoma.